Litcius/Paper detail

1359TiP RELATIVITY-104: First-line relatlimab (RELA) + nivolumab (NIVO) with chemotherapy vs nivo with chemotherapy in stage IV or recurrent non-small cell lung cancer (NSCLC): A phase II, randomized, double-blind study

Daniel Morgensztern, Arvind Chaudhry, Nicholas Iannotti, A. Acevedo, Gregor M. Balaburski, Ágnes Balogh, Solange Peters

2021Annals of Oncology14 citationsDOIOpen Access PDF

Topics & Concepts

MedicineNivolumabOncologyChemotherapyInternal medicinenon-small cell lung cancer (NSCLC)Lung cancerCancerImmunotherapyA549 cellCancer Immunotherapy and BiomarkersImmunotherapy and Immune ResponsesImmune cells in cancer
1359TiP RELATIVITY-104: First-line relatlimab (RELA) + nivolumab (NIVO) with chemotherapy vs nivo with chemotherapy in stage IV or recurrent non-small cell lung cancer (NSCLC): A phase II, randomized, double-blind study | Litcius